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Abstract 1 
 2 
Background: Recent clinical trials have demonstrated the efficacy of mechanical thrombectomy (MT) 3 
in acute ischaemic stroke. 4 
Aims: To determine the cost-effectiveness, value of future research and value of implementation of 5 
MT.  6 
Methods: Using UK clinical and cost data from the Pragmatic Ischaemic Stroke Thrombectomy 7 
Evaluation (PISTE) trial, we estimated the cost-effectiveness of MT over time horizons of 90-days and 8 
lifetime, based on a decision-analytic model, using all existing evidence. We performed a meta-9 
analysis of seven clinical trials to estimate treatment effects. We used sensitivity analysis to address 10 
uncertainty. Value of implementation analysis was used to estimate the potential value of additional 11 
implementation activities to support routine delivery of MT.  12 
Results: Over the trial period (90 days), compared with best medical care alone, MT incurred an 13 
incremental cost of £5,207 and 0.025 gain in QALY (incremental cost-effectiveness ratio (ICER) 14 
£205,279), which would not be considered cost-effective. However, MT was shown to be cost-15 
effective over a lifetime horizon, with an ICER of £3,466 per QALY gained.  The expected value of 16 
perfect information per patient eligible for MT in the UK is estimated at £3,178. The expected value 17 
of full implementation of MT is estimated at £1.3 billion over five years. 18 
Conclusion: MT was cost-effective compared with best medical care alone over a patient’s lifetime. 19 
On the assumption of 30% implementation being achieved throughout the UK healthcare system, we 20 
estimate that the population health benefits obtained from this treatment are greater than the cost 21 
of implementation.  22 
Trial registration: NCT01745692 23 
 24 
Background 25 
In acute ischaemic stroke caused by large artery occlusion of the anterior circulation, mechanical 26 
thrombectomy (MT) significantly increases the proportion of patients achieving favourable 27 
outcomes at day 90 on the modified Rankin Scale (mRS) (3-10). In 2015, the European Stroke 28 
Organisation (ESO) updated guidelines for the treatment of acute ischaemic stroke to recommend 29 
the use of mechanical thrombectomy (11). In 2016, the National Institute for Health and Care 30 
Excellence (NICE) updated their guidelines to include the use of mechanical thrombectomy in the UK 31 
(12).   32 
 33 
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Mechanical thrombectomy is a highly skilled procedure undertaken predominantly in neuroscience 1 
centres. Several studies have assessed the cost-effectiveness of thrombectomy in combination with 2 
best medical care compared with best medical care alone, and concluded thrombectomy to be cost-3 
effective (13-20) or potentially cost-saving (21-24). Best medical care includes intravenous 4 
thrombolysis with recombinant tissue plasminogen activator (IV rtPA) in the majority of cases, and in 5 
some clinical trials eligibility for IV rtPA was a mandatory inclusion criterion. Two model-based cost-6 
utility analyses, from the perspective of the UK NHS have been carried out (16, 23).  Based on meta-7 
analysis of five RCTs, compared with best medical care alone, thrombectomy in combination with 8 
best medical care was associated with an additional £7,061 per quality adjusted life year gained (16). 9 
In the other study, based on data from an RCT conducted in the US and Europe (the SWIFT-PRIME 10 
trial), thrombectomy in combination with best medical care was reported to be associated with cost-11 
savings of £33,190 per patient (23). However, the adoption and implementation of thrombectomy 12 
into routine practice requires additional investment in staff and capital equipment, and is also likely 13 
to require significant reorganisation of the healthcare system (25). Implementation in the UK has 14 
been limited due to combinations of staffing shortages in interventional and diagnostic 15 
neuroradiology, and the need for service reconfiguration. Most existing services currently cover only 16 
limited working hours (26-28). It is planned that the service should expand. Currently, one study has 17 
estimated the budget impact of adopting and implementing mechanical thrombectomy in Ireland 18 
(15). Based on treatment being delivered at two centres and treating 1,340 patients over five years, 19 
the cost of implementation was estimated to be 7.2 million euros over five years.  20 
 21 
Aims 22 
We conducted an economic evaluation to determine the cost-effectiveness of mechanical 23 
thrombectomy in combination best medical care compared with best medical care alone, in patients 24 
with acute ischaemic stroke. We undertook value of information analysis to estimate the monetary 25 
value of future research to reduce uncertainty in our estimate of cost-effectiveness. In adopting non-26 
drug interventions into clinical practice, challenges to implementation may have an impact on cost-27 
effectiveness. Value of implementation analysis was used to estimate the potential value of 28 
additional implementation activities to support the delivery of mechanical thrombectomy in routine 29 
practice.  30 
 31 
Methods 32 
 33 
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We estimated the cost-effectiveness of mechanical thrombectomy plus best medical care, compared 1 
with best medical care alone, in patients who had acute ischaemic stroke with large artery occlusive 2 
anterior circulation. Our analysis was performed over two time horizons: (i) 90-days – alongside the 3 
Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) trial (9) and (ii) lifetime – based on a 4 
decision-analytic model. The lifetime model was used to conduct one-way and probabilistic 5 
sensitivity analysis. We also estimated the potential value of future research and the value of 6 
implementation initiatives to support the introduction of thrombectomy in routine practice. The 7 
analysis was carried out from the perspective of the UK National Health Service (NHS) and Personal 8 
and Social Services (PSS). Costs and health benefits were discounted at 3.5% in line with national 9 
guidelines (29). Costs were expressed in UK pounds Sterling (2015/16 prices). 10 
 11 
Within-trial analysis 12 
 13 
The PISTE trial was a multicentre, randomised controlled clinical trial comparing mechanical 14 
thrombectomy plus best medical care including IV rtPA with best medical care including IV rtPA 15 
alone, in patients who had acute ischaemic stroke with large artery occlusive anterior circulation. 16 
Eligible patients were administered IV-tPA within 4.5 hours of stroke. Patients receiving additional 17 
mechanical thrombectomy were treated within a target time of <90 mins from IV-tPA start to 18 
arterial puncture. The primary outcome was the proportion of patients achieving functional 19 
independence mRS 0-2 at 90 days.  20 
 21 
We conducted an economic evaluation using data from the PISTE trial. Clinical outcome at 90 days 22 
was measured by mRS score. The mRS scores were converted into health utilities using a conversion 23 
algorithm (30). Health utilities were used to calculate quality-adjusted life-years (QALYs) over 90 24 
days. Resource use estimates collected during the trial included hospital bed days and cost of 25 
treatment with mechanical thrombectomy and best medical care. Unit costs were obtained from the 26 
literature (16, 31, 32) and applied to resource use.  27 
 28 
Mean patient costs and QALYs were estimated by using a generalised linear model (GLM) and 29 
adjusting for potential confounding (33). We adjusted for the following covariates: age group, 30 
National Institutes of Health Stroke Scale (NIHSS) group, and baseline health utility (QALY estimates 31 
only).  The appropriate family for the GLM was selected based on the results of the modified Park’s 32 
test. Our final cost model was based on the log link and gamma family. Our final QALY model was 33 
based on the identity link and Gauss family. All analyses were conducted in Stata 12.1 (StataCorp). 34 
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Based on the estimation of the final statistical model, the total cost and QALY difference between 1 
groups is based on the marginal prediction. 2 
 3 
Cost-effectiveness was expressed as the incremental cost-effectiveness ratio (ICER). We used 4 
nonparametric bootstrapping to calculate 95% confidence intervals for our estimate of the 5 
difference in mean cost and QALYs between treatment groups. 6 
Lifetime economic model 7 
 8 
The economic model was based on a previously published model (16) and is in line with the clinical 9 
pathway described for patients with acute ischaemic stroke who are eligible for treatment with both 10 
best medical care and mechanical thrombectomy, according to the guidance set out by NICE 11 
(National Institute for Clinical Excellence 2016) (figure 1).  12 
 13 
[INSERT FIGURE 1] 14 
 15 
The 90 days following stroke is represented by a decision tree. Although patients’ mRS score can 16 
vary appreciably over 90 days, we assume that the mRS score recorded at 90 days represents the 17 
most appropriate measure of functional status following treatment. Hence, at 90 days, patients are 18 
assumed to enter into one of three possible mutually exclusive health states (mRS 0-2: functional 19 
independence; mRS 3-5: functional dependence; mRS 6: death). Subsequently, a four-state Markov 20 
model is used to estimate costs and outcomes beyond three months. The model runs for 80 cycles of 21 
three months (20 years).  22 
 23 
We performed a meta-analysis to estimate the probabilities of patients resulting in the three mRS 24 
states using data from five RCT studies published in 2015 (3-7) and two recent trials – THRACE and 25 
PISTE trials (9, 10). Transition probabilities for the Markov model were sourced from the literature 26 
(34). Table 1 presents a list of parameters used in the lifetime model. Health utility estimates were 27 
obtained from published literature (35). Unit cost were obtained from the literature and applied to 28 
the recorded resource use associated with hospitalisation (procedure and stay costs), rehabilitation 29 
and community care costs (16, 32, 36). Non-UK currencies were converted to UK currency at the cost 30 
year reported in the literature and inflated to our reference year of 2015/16 prices using the 31 
Hospital & Community health services (HCHS) index (37, 38) 32 
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Table 1: Point estimates, probability distributions and source of parameter estimates used in the lifetime 1 
economic model 2 
Parameter Point estimate Probability distribution Source 
Decision tree    
mRS 0-2 (Best medical care 
+ MT) 
0.57 Conditional beta distribution Meta-analysis 
mRS 3-5 (Best medical care 
+ MT) 
0.27 Conditional beta distribution Meta-analysis 
mRS 6 (Best medical care + 
MT) 
0.16 Conditional beta distribution Meta-analysis 
mRS 0-2 (Best medical care 
only) 
0.26 Conditional beta distribution Meta-analysis 
mRS 3-5 (Best medical care 
only) 
0.55 Conditional beta distribution Meta-analysis 
mRS 6 (Best medical care 
only) 
0.19 Conditional beta distribution Meta-analysis 
Markov model    
Year 1    
From independent (mRS 0-
2) to: 
   
mRS 0-2 0.955 Conditional beta distribution Davis (2012)  
mRS 3-5 0.024 Conditional beta distribution Davis (2012)  
recurrent stroke 0.013 Conditional beta distribution Davis (2012)  
dead 0.008 Conditional beta distribution Davis (2012)  
From dependent (mRS 3-5) 
to: 
 Conditional beta distribution Davis (2012)  
mRS 0-2 0.029 Conditional beta distribution Davis (2012)  
mRS 3-5 0.919 Conditional beta distribution Davis (2012)  
recurrent stroke 0.013 Conditional beta distribution Davis (2012)  
dead 0.039 Conditional beta distribution Davis (2012)  
After year 1   Davis (2012)  
From independent (mRS 0-
2) to: 
  Davis (2012)  
mRS 0-2 0.979 Conditional beta distribution Davis (2012)  
mRS 3-5 0 Conditional beta distribution Davis (2012)  
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recurrent stroke 0.013 Conditional beta distribution Davis (2012)  
dead 0.008 Conditional beta distribution Davis (2012)  
From dependent (mRS 3-5) 
to: 
 Conditional beta distribution Davis (2012)  
mRS 0-2 0 Conditional beta distribution Davis (2012)  
mRS 3-5 0.948 Conditional beta distribution Davis (2012)  
recurrent stroke 0.013 Conditional beta distribution Davis (2012)  
dead 0.039 Conditional beta distribution Davis (2012)  
Recurrent stroke  Conditional beta distribution Davis (2012)  
(Best medical care + MT) 
mRS 0-2 
0.867 Conditional beta distribution Davis (2012)  
(Best medical care + MT) 
mRS 3-5 
0.104 Conditional beta distribution Davis (2012)  
(Best medical care + MT) 
recurrent stroke 
0 Conditional beta distribution Davis (2012)  
(Best medical care + MT) 
dead 
0.029 Conditional beta distribution Davis (2012)  
(Best medical care alone) 
mrs 0-2 
0.834 Conditional beta distribution Davis (2012)  
(Best medical care alone) 
mrs 3-5 
0.137 Conditional beta distribution Davis (2012)  
(Best medical care alone) 
recurrent stroke 
0 Conditional beta distribution Davis (2012)  
(Best medical care alone) 
dead 
0.029 Conditional beta distribution Davis (2012)  
Health utilities    
Independent 0.74 Beta distribution Dorman (2000) 
Dependent 0.38 Beta distribution Dorman (2000) 
Recurrent 0.34 Beta distribution Dorman (2000) 
Costs     
Best medical care £1,919 Gamma distribution British National 
Formulary 
MT £8,912 Gamma distribution Ganesalinham (2015), 
Davis (2012) 
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first 3 months:    
Independent £7,302.83 Gamma distribution Ganesalinham (2015) 
Dependent £15,627.49 Gamma distribution Ganesalinham (2015) 
Fatal £10,039.42 Gamma distribution Ganesalingam (2015) 
Recurrent £380.46 Gamma distribution Ganesalingam (2015) 
Ongoing per 3 months:    
Independent £498.42 Gamma distribution Ganesalingam (2015) 
Dependent £1,339.64 Gamma distribution Ganesalingam (2015) 
 1 
Incremental analysis 2 
 3 
Cost-effectiveness was expressed as the Incremental cost-effectiveness ratio (ICER) and the 4 
incremental Net Monetary Benefit (NMB). ICERs are calculated as follows: 5 
Incremental cost-effectiveness ratio (ICER) = ΔCosts/ΔQALY 6 
Where ΔCosts is the difference in total costs between: and ΔQALY is the difference in utility between 7 
interventions. 8 
The NMB is a measure of the health benefit, expressed in monetary terms, which incorporates the 9 
cost of the new strategy, the health gain obtained, and the societal willingness to pay for health 10 
gains. The NMB is calculated using the following formula: 11 
Incremental NMB = (ΔE*WTP) - ΔC 12 
E = effectiveness: WTP = willingness-to-pay threshold (£20,000 in the UK); C = cost 13 
Uncertainty 14 
 15 
Uncertainty around the parameter estimates used in our model was fully characterised and 16 
propagated through to the model results by conducting probabilistic sensitivity analysis (PSA). This 17 
was done by defining parameter values using distributions rather than point estimates. The model 18 
was then run 5,000 times with a value randomly drawn from the assigned probability distribution. 19 
This produced a distribution of model outputs which was represented visually on the cost-20 
effectiveness plane. Cost-effectiveness acceptability curves (CEAC) were used to represent the 21 
probability that an intervention would be cost-effective compared to the control group at a range of 22 
willingness-to-pay thresholds. 23 
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We conducted one-way sensitivity analysis on the key parameters driving the cost-effectiveness 1 
estimate of mechanical thrombectomy in our model. We tested: the cost of the mechanical 2 
thrombectomy procedure, the health utility associated with functional independence, dependence 3 
and death, the proportion of patients achieving functional independence, dependence and death, 4 
following treatment with mechanical thrombectomy or best medical care alone. We tested the 5 
impact on the model’s estimate of cost-effectiveness (i.e. the ICER) of varying each of these 6 
parameters individually by +/- 20%. Further details are given in the appendix. 7 
 8 
Value of information 9 
 10 
Value of information analysis on the expected value of perfect information (EVPI) was carried out to 11 
quantify the potential value of further research based on the difference between the expected NMB 12 
with perfect information and with existing information. The EVPI represents the amount a decision 13 
maker should be willing to pay to eliminate uncertainty regarding which intervention is the best 14 
option. This uncertainty is characterised in the model in terms of parameter uncertainty and is 15 
addressed through the use of PSA which produces a distribution of outcomes, in terms of costs and 16 
QALYs, for each treatment. The difference between the NMB, based on a decision made with perfect 17 
information (i.e. no uncertainty) and with current information, represents the EVPI. We also 18 
estimated the expected value of perfect parameter information (EVPPI). This estimates the value of 19 
reducing the uncertainty relating to specific parameters in your model. For the purpose of this 20 
analysis, we grouped together groups of related model parameters as follows; i) parameters for mRS 21 
state at 90 days from clinical trial data; ii) utility parameters; iii) cost parameters; iv) lifetime 22 
transition parameters. 23 
 24 
It has been estimated that approximately 11,000 patients with acute ischaemic stroke are eligible for 25 
mechanical thrombectomy per year in the UK (39-41). For the analysis, we assumed the “effective 26 
population” (discounted population) which stands to benefit from this treatment to be 51,404 27 
patients over a five year period, and that the lifetime of the new technology to be five years.  28 
 29 
Value of implementation 30 
 31 
We calculated the value of implementation as the value of perfect implementation minus the cost of 32 
implementation (42), measured over a five-year time horizon. We estimate the maximum potential 33 
value of implementation as the net monetary benefit of achieving 100% implementation across the 34 
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UK (51,404 patients over five years). We then subtracted from this the cost of 27 comprehensive 1 
stroke centres across the UK necessary to perform this procedure. We included costs of ongoing 2 
staff salaries and initial set-up costs - such as training and equipment (full details are given in the 3 
appendix). We also estimated the “break-even” point at which the NMB obtained from the 4 
proportion of eligible patients treated is equal to the cost of implementation. 5 
 6 
Results 7 
Within-trial analysis 8 
The results of the within-trial analysis found that mechanical thrombectomy plus best medical care, 9 
compared to best medical care alone, had a total cost of £17,157 compared with £11,949. Over the 10 
course of the trial (90 days), the QALYs gained in the intervention group were 0.142, compared with 11 
0.117 in the control group. This equates to an incremental cost of £5,207 and 0.025 QALYs 12 
associated with the addition of mechanical thrombectomy to best medical care alone and an ICER of 13 
£205,279 per QALY gained. The bootstrapped mean cost difference between groups was £5,207 14 
(95% CI: -£1,458, £11,873) and the mean QALY difference was 0.026 (95% CI: -0.008, 0.059). 15 
Lifetime economic model 16 
The results of the economic model found that mechanical thrombectomy plus best medical care, 17 
compared to best medical care alone, had a total cost of £46,684 compared with £39,035 (table 2). 18 
Over a lifetime horizon, the QALYs gained in the intervention group were 7.614, compared with 19 
5.408 in the control group. This equates to an incremental cost of £7,649 and 2.207 QALYs 20 
associated with the addition of mechanical thrombectomy to best medical care alone and an 21 
incremental cost-effectiveness ratio of £3,466 per QALY gained and an incremental NMB of £36,484 22 
per patient. 23 
Table 2: Lifetime economic model results, in terms of lifetime costs and QALYs, for MT plus best medical therapy compared 24 
with best medical therapy alone (outcomes are presented per patient) 25 
Treatment  Cost 
(£)  
QALYs 
gained  
Incremental 
cost (£)  
Incremental 
QALYs 
gained  
Incremental 
cost/QALY 
gained (ICER)  
Incremental 
NMB  
Best 
medical 
care  
 
£39,035  
 
5.408  
 
 
    
Best medical 
care + 
Mechanical 
thrombectomy  
 
£46,684  
 
7.614  
 
£7,649  
 
2.207  
 
£3,466  
 
£36,484  
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Probabilistic sensitivity analysis 1 
 2 
The cost-effectiveness plane shows the results of running the model 5,000 times and recording the 3 
difference in cost and effectiveness between the mechanical thrombectomy and best medical care 4 
(figure 2). Although most data points are observed in the upper right quadrant of the plane 5 
(representing the scenario of ‘more costly and more effective’), there is considerable uncertainty 6 
surrounding the extent and existence of the additional expected costs and the existence and extent 7 
of the additional expected QALYs. 8 
The cost-effectiveness acceptability curve (CEAC) shows the probability of mechanical 9 
thrombectomy being cost-effective for different levels of willingness-to-pay thresholds, compared 10 
with best medical care alone (figure 3). The CEAC shows that, at a willingness-to-pay threshold of 11 
£20,000 per QALY gained, mechanical thrombectomy has a 76% probability of being cost-effective, 12 
compared with best medical care alone. 13 
[INSERT FIGURE 2] 14 
[INSERT FIGURE 3] 15 
One-way sensitivity analysis 16 
 17 
We conducted one-way sensitivity analysis on the key parameters driving the cost-effectiveness 18 
estimate of mechanical thrombectomy in our model. Our results showed that varying all of these key 19 
parameters within our model had no impact on the decision problem, i.e. all ICER estimates remain 20 
below £20,000 per QALY. The parameter which had the greatest negative impact on cost-21 
effectiveness (i.e. increased the ICER) was the proportion of patients achieving functional 22 
independence (mRS 0-2) after receiving mechanical thrombectomy.  23 
 24 
Value of information 25 
 26 
The expected value of perfect information per patient affected by the decision to recommend 27 
treatment using mechanical thrombectomy is estimated at £3,178 per person. Based on our 28 
assumptions of 51,404 eligible patients over a five-year lifetime of this technology, at a willingness-29 
to-pay of £20,000 per QALY gained, this equates to an expected value of perfect information of £163 30 
million over a five-year period for the UK population (FIGURE 4).  31 
 32 
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[INSERT FIGURE 4] 1 
 2 
The expected value of perfect parameter information suggests that all of the value of reducing 3 
parameter uncertainty in our model is generated from the lifetime transition probabilities for 4 
patients following the 90-day period after stroke. 5 
 6 
Value of implementation 7 
 8 
We estimate the value of perfect implementation as the NMB from mechanical thrombectomy 9 
(£36,484 per person) multiplied by the effective population (51,404). This implies that the expected 10 
value of perfect implementation in UK would be £1.7 billion. We estimate a cost of £16,404,911 per 11 
comprehensive stroke centre, over a five-year period. Hence, a total cost of £443 million to 12 
implement this procedure across the UK in 27 comprehensive stroke centres over five years (a full 13 
breakdown of the cost calculation is given in Table 3 and details of assumptions are given in 14 
supplementary material). This suggests an expected value of implementation of £1.3 billion over five 15 
years. We estimate the “break-even” value of implementation activity point at approximately 30% 16 
implementation (approx. 3,084 patients per year). Below this point, the cost of implementing 17 
mechanical thrombectomy into routine practice is expected to be greater than the benefit, in NMB 18 
terms. 19 
Table 3: Breakdown of cost calculation for the set-up of a comprehensive stroke unit capable of performing MT, 20 
including capital costs, staff and training costs, over a five-year period. 21 
Resource Units 
required 
Unit cost Set-up 
costs 
Year 1 Year 2 Year 3 Year 4 Year 5 Resource costs 
per stroke unit 
(5 years) 
Ongoing costs                   
Interventional 
neuroradiologist 
(year 1) 
3 £116,451 £0 £349,352           
(year 2) 3 £119,455     £358,365         
(year 3) 3 £122,537       £367,611       
(year 4) 4 £125,699         £502,794     
(year 5) 5 £128,942           £644,708 £2,222,831 
Anaesthetists 
(year 1) 
3 £17,000 £0 £51,000           
(year 2) 3 £17,439     £52,316         
(year 3) 3 £17,889       £53,666       
(year 4) 4 £18,350         £73,400     
(year 5) 4 £18,823           £75,294 £305,675 
Anaesthetist 
assistant (year 1) 
3 £6,383 £0 £19,148           
(year 2) 3 £6,547     £19,642         
(year 3) 3 £6,716       £20,149       
13 
 
(year 4) 4 £6,890         £27,559     
(year 5) 4 £7,067           £28,270 £114,769 
Theatre nurse 
(year 1) 
5 £6,383 £0 £31,914           
(year 2) 5 £6,547     £32,737         
(year 3) 5 £6,716       £33,582       
(year 4) 5 £6,890         £34,448     
(year 5) 5 £7,067           £35,337 £168,019 
Recovery nurse 
(year 1) 
1 £5,153 £0 £5,153           
(year 2) 1 £5,286     £5,286         
(year 3) 1 £5,422       £5,422       
(year 4) 1 £5,562         £5,562     
(year 5) 1 £5,706           £5,706 £27,128 
Radiographer 
(year 1) 
5 £4,983 £0 £24,914           
(year 2) 5 £5,111     £25,557         
(year 3) 5 £5,243       £26,216       
(year 4) 5 £5,379         £26,893     
(year 5) 5 £5,517           £27,586 £131,166 
Radiologist (year 
1) 
2 £23,290 £0 £46,580           
(year 2) 2 £23,891     £47,782         
(year 3) 2 £24,507       £49,015       
(year 4) 2 £25,140         £50,279     
(year 5) 2 £25,788           £51,577 £245,233 
Stroke physician 
(year 1) 
1.4 £23,290 £0 £32,606           
(year 2) 1.4 £23,891     £33,447         
(year 3) 1.4 £24,507       £34,310       
(year 4) 1.4 £25,140         £35,196     
(year 5) 1.4 £25,788           £36,104 £171,663 
Ambulance 
transfer per MT 
(year 1) 
1 £231 £0 £12,833           
(year 2) 1 £237     £26,329         
(year 3) 1 £243       £54,016       
(year 4) 1 £249         £83,115     
(year 5) 1 £256           £104,206 £280,499 
Helicopter 
transfer per MT 
(year 1) 
0.17 £2,900 £0 £27,389           
(year 2) 0.17 £2,975     £56,191         
(year 3) 0.17 £3,052       £115,282       
(year 4) 0.17 £3,130         £177,384     
(year 5) 0.17 £3,211           £222,396 £598,641 
MT device costs 
(stent retriever, 
catheter, 
procedure pack, 
drapes, gowns, 
gloves, sheath) 
(year 1) 
1 £4,878 £0 £271,000           
(year 2) 1 £5,004     £555,984         
14 
 
(year 3) 1 £5,133       £1,140,65
6 
      
(year 4) 1 £5,265         £1,755,12
7 
    
(year 5) 1 £5,401           £2,200,501 £5,923,267 
CT angiography 
per MT (year 1) 
1 £1,200 £0 £66,667           
(year 2) 1 £1,231     £136,773         
(year 3) 1 £1,263       £280,604       
(year 4) 1 £1,295         £431,766     
(year 5) 1 £1,329           £541,329 £1,457,138 
CT perfusion per 
MT (year 1) 
1 £60 £0 £3,333           
(year 2) 1 £62     £6,839         
(year 3) 1 £63       £14,030       
(year 4) 1 £65         £21,588     
(year 5) 1 £66           £27,066 £72,857 
Nurse to 
accompany CT 
scan per MT (year 
1) 
1 £49 £0 £2,722           
(year 2) 1 £50     £5,585         
(year 3) 1 £52       £11,458       
(year 4) 1 £53         £17,630     
(year 5) 1 £54           £22,104 £59,500 
Nurse 
assessment per 
MT (year 1) 
1 £4 £0 £218           
(year 2) 1 £4     £447         
(year 3) 1 £4       £917       
(year 4) 1 £4         £1,410     
(year 5) 1 £4           £1,768 £4,760 
Routine nurse 
observation per 
MT (year 1) 
1 £16 £0 £898           
(year 2) 1 £17     £1,843         
(year 3) 1 £17       £3,781       
(year 4) 1 £17         £5,818     
(year 5) 1 £18           £7,294 £19,635 
Junior staff 
review per MT 
(year 1) 
1 £13 £0 £700           
(year 2) 1 £13     £1,436         
(year 3) 1 £13       £2,946       
(year 4) 1 £14         £4,534     
(year 5) 1 £14           £5,684 £15,300 
Consultant 
review at 24 
hours per MT 
(year 1) 
1 £35 £0 £1,944           
(year 2) 1 £36     £3,989         
(year 3) 1 £37       £8,184       
(year 4) 1 £38         £12,593     
(year 5) 1 £39           £15,789 £42,500 
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Training and set-
up costs 
  £40               
Angio suite 1 £1,800,00
0 
£1,800,
000 
£160,000 £164,128 £168,363 £172,706 £177,162 £2,642,359 
Interventional 
neuroradiologist 
(training) 
5 £300,000 £1,500,
000 
£0         £1,500,000 
Anaesthetists 
(training) 
4 £35,798 £143,19
2 
£0         £143,192 
Anaesthetist 
assistant 
(training) 
4 £97 £387 £0         £387 
Theatre nurse 
(training) 
5 £20,000 £100,00
0 
£0         £100,000 
Recovery nurse 
(training) 
1 £97 £97 £0         £97 
Radiologist 
(training for 
diagnostic CT) 
2 £14,915 £29,830 £0         £29,830 
Radiographer 
(training for 
diagnostic CT) 
5 £10,937 £54,685 £0         £54,685 
Stroke physician 
(training for 
diagnostic CT) 
1.4 £52,700 £73,780 £0         £73,780 
                    
No. of patients 
treated in UK 
      1500 3000 6000 9000 11000   
No of patients 
treated per 
centre 
      56 111 222 333 407   
Annual costs     £3,701,
971 
£1,108,37
3 
£1,534,67
7 
£2,390,20
9 
£3,439,80
3 
£4,229,880   
Cost per MT       £19,951 £13,812 £10,756 £10,319 £10,382   
              Total cost per centre over five years: £16,404,911 
 1 
Discussion 2 
 3 
Our results indicate that mechanical thrombectomy plus best medical care, compared with best 4 
medical care alone, meets standard criteria to be considered a cost-effective use of resources in a 5 
UK health service setting. The results of our study are consistent with other UK economic 6 
evaluations which suggest the cost-effectiveness of mechanical thrombectomy over a patient’s 7 
lifetime perspective (16, 23). One UK study found mechanical thrombectomy to be cost-saving.  This 8 
is partly driven by the assumption of higher long-term care costs associated with disability after 9 
stroke and the savings resulting from avoidance of disability due to treatment with mechanical 10 
thrombectomy.  Furthermore, the proportion of patients achieving functional independence (mRS 0-11 
2) following mechanical thrombectomy is 60% (obtained from SWIFT-PRIME trial), compared with 12 
our estimate of 57%. 13 
 14 
Our results suggest that the use of mechanical thrombectomy is unlikely to be cost-effective over a 15 
90-day time horizon, based on data from the UK-based PISTE trial. This is due to a very small 16 
difference in health benefits between the two treatments observed in the trial. The incremental cost 17 
of mechanical thrombectomy over a 90-day period was £5,207, compared with £7,649 over a 18 
16 
 
lifetime horizon. However, the QALY gain over a 90-day horizon was 0.025 QALYs, compared with 1 
2.207 QALYs over a lifetime horizon. This implies that, over a lifetime horizon, there is a 2 
proportionally greater increase in QALYs than costs. The premature termination of the PISTE trial, 3 
and hence reduced sample size and some treatment crossovers, may have had an impact on the 4 
QALY different between treatment groups. However, the estimated effect sizes were similar to those 5 
seen in other mechanical thrombectomy trials, and results were significant in the per protocol 6 
population despite small sample size (43). It should also be noted that best medical care in all 7 
patients in the PISTE trial included IV rtPA, in common with some other MT trials (EXTEND-IA, SWIFT-8 
Prime), while other trials permitted inclusion of thrombolysis-ineligible patients (MR CLEAN, ESCAPE, 9 
REVASCAT). The effect of MT on very poor functional outcomes is greater among thrombolysis-10 
ineligible patients (44), thus PISTE may have under-estimated the proportion of highly dependent 11 
outcomes. Further, PISTE also required  good baseline function, as measured by estimated pre-12 
stroke mRS score, which may have influenced the treatment effect observed in the trial. 13 
 14 
Our value of information analysis suggests that further research costing less than £163 million has 15 
the potential to be considered a cost-effective use of resources. This is because the return on the 16 
investment from further research, in terms of the costs and/or health benefits gained from choosing 17 
an alternative strategy based on the new evidence, is expected to be no higher than the figure of 18 
£163 million. The expected value of perfect parameter information suggests that all of the value of 19 
reducing parameter uncertainty in our model is generated from the lifetime transition probabilities 20 
for patients following the 90-day period after stroke. Intuitively this makes sense. The recent clinical 21 
trials have demonstrated the efficacy of mechanical thrombectomy, compared with best medical 22 
care, over a 90-day time horizon. The results of our within-trial cost-effectiveness analysis of the 23 
PISTE trial suggests that over 90-days, the benefits associated with mechanical thrombectomy do 24 
not outweigh the costs. The result is reversed over the lifetime of a patient, as the cost and utility 25 
gain resulting from reduced disability from stroke have proportionally greater influence. Hence, the 26 
finding of cost-effectiveness of mechanical thrombectomy comes from our estimates of what 27 
happens to a patient over their lifetime, i.e. it comes from our lifetime model.  Further research in 28 
this area could take the form of a follow-up study aimed at identifying the mRS states of patients 29 
following treatment with mechanical thrombectomy at future time points (i.e. 5 years, 10 years). 30 
 31 
Our lifetime cost-effectiveness model used clinical evidence from seven RCTs of mechanical 32 
thrombectomy (using second generation stent retrievers), but did not consider subsequent trials 33 
indicating benefit from mechanical thrombectomy in patients presenting in later time windows (6-24 34 
17 
 
hours) based on additional imaging selection criteria (40, 41). In order to estimate the cost of 1 
routinely providing mechanical thrombectomy across the UK, it was necessary to make some 2 
assumptions (see appendix). In terms of staffing costs, our results are likely to be an overestimate. 3 
This is because we have chosen to provide the cost of a full-time equivalent for some staff 4 
(interventional neuroradiologist) to reflect the need to have these staff available on demand over a 5 
24-hour service focussed on delivering MT. In practice, it is likely that a proportion of these staff will 6 
spend their time on activities unrelated to thrombectomy. Support staff (e.g. anaesthetist) are 7 
assumed to spend a portion of their time supporting MT delivery, and the remaining time delivering 8 
other services. However, precise numbers required to populate a rota capable of providing a 24-9 
hour MT service is highly uncertain and will vary by region and stroke services available. In addition, 10 
we have included the full cost of an angiography suite required to undertake the procedure to 11 
reflect the initial set-up costs required, however, in practice, this equipment will be available for 12 
other activities and hence not all costs associated with the suite will be attributable to 13 
thrombectomy. 14 
 15 
The ability to identify patients mostly likely to benefit from mechanical thrombectomy and to triage 16 
these patients from stroke onset to initiation of treatment within the required time period presents 17 
a challenge. To meet this challenge, significant system reorganisation will be required (25). The 18 
clinical trial evidence relates to patients who were predominantly able to receive treatment within 6 19 
hours from stroke onset, a small minority being treated beyond 6 hours in the two trials with longer 20 
time windows (ESCAPE 12 hours and REVASCAT 8 hours). Patient level meta-analysis confirms 21 
steeply declining benefit with later treatment even within the first 6 hours (45). As such, strategies 22 
aimed at minimising door-to-needle times are recommended. The role of imaging in the selection of 23 
patients for mechanical thrombectomy, as undertaken in both trials of thrombectomy beyond the 6 24 
hour time window (46, 47), remains uncertain for those treated within the first 6 hours, since only 25 
two trials mandated similar selection criteria (48, 49) . The role of regional hospitals (“primary stroke 26 
centres”), unable to deliver mechanical thrombectomy, in the early administration of IV-tPA prior to 27 
transfer to a comprehensive stroke centre - the so called “drip and ship” model vs. the “mothership” 28 
model - is likely to require local planning dependent on service characteristics and transport 29 
networks (50). The need to maintain a minimum institutional and individual workload to maintain 30 
skills would likely pose a challenge to regional hospitals. Further research in these areas will 31 
contribute to the discussion around optimal system organisation and will impact on the cost-32 
effectiveness of mechanical thrombectomy that will be observed in routine practice. The results of 33 
our implementation analysis suggest that the cost-effectiveness of mechanical thrombectomy in 34 
18 
 
practice is not contingent on achieving full implementation. Indeed, our results suggest that any 1 
level of implementation greater than 30% is likely to be a cost-effective use of resources.  2 
 3 
Conclusion 4 
 5 
Based on a lifetime horizon, our economic model suggests that mechanical thrombectomy is cost-6 
effective compared with best medical care. The CEAC showed that, at a willingness-to-pay threshold 7 
of £20,000 per QALY gained, mechanical thrombectomy has a 76% probability of being cost-8 
effective, compared with best medical care alone. Our value of information analysis suggests that 9 
there is value in future research aimed at reducing the uncertainty around transitions between mRS 10 
states in the longer term. On the assumption of full implementation being achieved throughout the 11 
UK healthcare system, we estimate that the value of implementation is greater than the cost of 12 
implementation. We find that this result holds for any level of implementation greater than 13 
approximately 30%. 14 
Funding 15 
This study was funded by the National Institute for Health Research (NIHR). The NIHR has no role in 16 
the design, conduct or interpretation of the study. 17 
Conflict of interest 18 
The PISTE Trial Steering Committee was chaired by GAF (Stroke Association funded phase) and by H 19 
Markus (HTA phase). JF was the lay representative on the Trial Steering Committee and participated 20 
in all trial design and management decisions. The Data Monitoring Committee was chaired by K R 21 
Lees (Stroke Association phase) and by T Robinson (HTA phase); and included S Lewis (Stroke 22 
Association phase), J Norrie (HTA phase) and A Molyneux (throughout). 23 
 24 
Copyright/licence statement 25 
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of 26 
all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats 27 
and media (whether known now or created in the future), to i) publish, reproduce, distribute, display 28 
and store the Contribution, ii) translate the Contribution into other languages, create adaptations, 29 
reprints, include within collections and create summaries, extracts and/or, abstracts of the 30 
Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all 31 
subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third 32 
19 
 
party material where-ever it may be located; and, vi) licence any third party to do any or all of the 1 
above. 2 
Patient/public involvement 3 
N/A 4 
Contribution statement 5 
RH undertook the analysis and drafted the paper. OW designed the study. KM was Principle 6 
Investigator on the PISTE trial. All co-authors reviewed and commented on the paper. 7 
Summary statement 8 
What is already known on the topic: the clinical effectiveness of mechanical thrombectomy (MT) has 9 
been established in multiple clinical trials. Clinical trials from non-UK data have been combined with 10 
UK cost data to estimate potential cost-effectiveness of MT in a UK setting. 11 
What this study adds: This is the first study to utilise UK clinical trial data, resource use data and cost 12 
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